{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+2&page=30", "query": { "intervention": "Active Comparator 2", "page": 30 }, "page_size": 10 }, "pagination": { "page": 30, "page_size": 10, "total_count": 941, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+2&page=31&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Active+Comparator+2&page=29&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-26T07:58:07.017Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01413516", "title": "Varenicline In-Patient Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Smoking Cessation" ], "interventions": [ { "name": "Smoking cessation counseling", "type": "BEHAVIORAL" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Varenicline", "type": "DRUG" } ], "intervention_types": [ "BEHAVIORAL", "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2011-08", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2023-11-14", "last_synced_at": "2026-10-26T07:58:07.017Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413516" }, { "nct_id": "NCT06229275", "title": "Comparing Effectiveness of Physician-assisted Versus Self-assisted Pap Smear Collection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical Cancer Screening" ], "interventions": [ { "name": "Pap smear collection using the Personal Pap Smear (PPS) Device", "type": "DEVICE" }, { "name": "Active Comparator: Pap smear collection using the Rovers Cervex-Brush", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Morehouse School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "21 Years to 65 Years · Female only" }, "enrollment_count": 200, "start_date": "2024-07-25", "completion_date": "2026-03-30", "has_results": false, "last_update_posted_date": "2025-07-20", "last_synced_at": "2026-10-26T07:58:07.017Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06229275" }, { "nct_id": "NCT00563264", "title": "KAN-DO: A Family-based Intervention to Prevent Childhood Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Prevention & Control", "Postpartum Period" ], "interventions": [ { "name": "KAN-DO", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 832, "start_date": "2007-10", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2014-07-11", "last_synced_at": "2026-10-26T07:58:07.017Z", "location_count": 2, "location_summary": "Durham, North Carolina • Greensboro, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Greensboro", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00563264" }, { "nct_id": "NCT00784875", "title": "An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Primary Insomnia", "Secondary Insomnia" ], "interventions": [ { "name": "LY2624803", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "zolpidem", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 643, "start_date": "2008-10", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2012-02-29", "last_synced_at": "2026-10-26T07:58:07.017Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 46 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00784875" }, { "nct_id": "NCT02973477", "title": "Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type2 Diabetes", "Cardiovascular Diseases" ], "interventions": [ { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2017-01-12", "completion_date": "2019-08-22", "has_results": true, "last_update_posted_date": "2020-10-22", "last_synced_at": "2026-10-26T07:58:07.017Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02973477" }, { "nct_id": "NCT01682512", "title": "Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "BI 695500", "type": "DRUG" }, { "name": "Rituxan®", "type": "DRUG" }, { "name": "MabThera®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 294, "start_date": "2012-09-05", "completion_date": "2016-10-12", "has_results": true, "last_update_posted_date": "2018-01-30", "last_synced_at": "2026-10-26T07:58:07.017Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01682512" }, { "nct_id": "NCT00784719", "title": "A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Dry Eye Syndromes" ], "interventions": [ { "name": "CP-690,550", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "CP-690,550 Vehicle", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 327, "start_date": "2008-11", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2013-04-09", "last_synced_at": "2026-10-26T07:58:07.017Z", "location_count": 27, "location_summary": "Chandler, Arizona • Peoria, Arizona • Phoenix, Arizona + 22 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Artesia", "state": "California" }, { "city": "Centennial", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00784719" }, { "nct_id": "NCT00865371", "title": "A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fed Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Abrika Bupropion 150 mg Extended-Released Tablet", "type": "DRUG" }, { "name": "Wellbutrin SR® 150 mg Extended-Release Tablet, single dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Actavis Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 26, "start_date": "2004-09", "completion_date": "2004-09", "has_results": false, "last_update_posted_date": "2010-08-16", "last_synced_at": "2026-10-26T07:58:07.017Z", "location_count": 1, "location_summary": "Fort Myers, Florida", "locations": [ { "city": "Fort Myers", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00865371" }, { "nct_id": "NCT03346057", "title": "Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Reversal of Neuromuscular Blockade" ], "interventions": [ { "name": "Sugammadex 2 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 4 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 16 mg/kg", "type": "DRUG" }, { "name": "Neostigmine + Glycopyrrolate", "type": "DRUG" }, { "name": "Rocuronium", "type": "DRUG" }, { "name": "Vecuronium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 344, "start_date": "2017-12-20", "completion_date": "2019-09-04", "has_results": true, "last_update_posted_date": "2020-10-08", "last_synced_at": "2026-10-26T07:58:07.017Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Loma Linda", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03346057" }, { "nct_id": "NCT03909165", "title": "Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Neuromuscular Blockade" ], "interventions": [ { "name": "Sugammadex 2 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 4 mg/kg", "type": "DRUG" }, { "name": "Neostigmine + Glycopyrrolate", "type": "DRUG" }, { "name": "Neostigmine + Atropine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "2 Years", "sex": "ALL", "summary": "1 Day to 2 Years" }, "enrollment_count": 145, "start_date": "2019-07-23", "completion_date": "2023-09-21", "has_results": true, "last_update_posted_date": "2025-07-25", "last_synced_at": "2026-10-26T07:58:07.017Z", "location_count": 7, "location_summary": "Palo Alto, California • Miami, Florida • Oklahoma City, Oklahoma + 4 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03909165" } ] }